



APPLICATION NO.: 10/563,471

FILED: JANUARY 3, 2006

APPLICANT: LIN WANG ET AL.

**VERIFICATION AND ENGLISH TRANSLATION OF
CHINESE PRIORITY DOCUMENT NO. 03148547.2**

VERIFICATION OF TRANSLATION

I, CHEN XIN, hereby declare that I am an experienced translator, including translations between the Chinese and the English languages, that I personally translated the accompanying Chinese language U.S. Patent Application document into the accompanying English language Patent Application document, and the later document is an accurate English translation of the former document

Dated 18th September, 2009




Signature: CHEN XIN

C-GLYCOSYLIOSFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, PREPARATION AND USE OF THE SAME

TECHNICAL FIELD

The present invention relates to C-Glycosylisoflavones having alkylaminoalkoxyl substituent and pharmaceutically acceptable salts thereof, a process for the preparation thereof, pharmaceutical compositions comprising an effective amount of a compound of the formula (I). Which composition is used for the treatment or prevention of cardio- and cerebrovascular diseases, in particular for the treatment of various cardiocerebral hypoxic-ischemic diseases, for the treatment or prevention of diabetes mellitus and complications thereof, and for the treatment or prevention of chemical poisoning, in particular alcoholism.



BACKGROUND ARTS

Puerarin (formula (I), wherein $R_1 = R_2 = R_3 = H$) is an effective ingredient in Kudzuvine Root (*Radix Puerariae*), a leguminous plant, and has a chemical name of 4',7-dihydroxy-8- β -D-C-glycosylisoflavone. In the recent decades, the mechanism and applications of puerarin are studied, and it is proven that puerarin does have effects such as expanding coronary artery, improving cardiac contractility, protection global ischemia cardiac muscle, promoting blood circulation, etc. At present, puerarin is widely used clinically

for the treatment of coronary heart disease, angina pectoris, myocardial infarct, arrhythmia, cardiac failure, vertebro-basilar artery insufficiency, hyperviscosity syndrome, hypertension, cerebral thrombosis, cerebral edema, retinal arterial obstruction, retinal vein obstruction, sudden deafness, diabetes and complications thereof, pesticide intoxication, alcoholism, and tumors, etc. (Wang Jing, Ji Min, Hua Weiyi, et al., Study Achievement of Puerarin, *Yaoxue Xuebao (Acta Pharmaceutica Sinica)*, 2003, 27(2):70-3). At present, cardio- and cerebrovascular diseases are the primary diseases causing adult death in China. Being a new drug for improving cardio- and cerebrovascular blood circulation, puerarin has a novel structure and definite therapeutic effects, and thus is important for the treatment of these diseases.

It has been reported in the prior arts that puerarin has some adverse effects in clinical applications, which mainly manifest in febrile, allergies, drug eruptions, transient hemoglobinuria, etc. Cheng Weijin, et al. (*Yaowu Liuxingbing Zazhi (Chinese Journal of Pharmacoepidemiology)*, 2000, 9(3):129-130) had made an investigation on 568 patients who had administered with puerarin, and the results indicates that the total incidence rate of febrile was 5.81%, there was no significant difference in age and gender and in dosage, and the febrile mainly related to the days of sustained medication. The patients' body temperature gradually decreased to normal level after drug withdrawal or the patients were treated by antipyresis simultaneously. The treatment with antibiotics was ineffective. This might be caused by the toxic effect of drug accumulation during the long time of therapy; and the drug might penetrate the blood brain barrier, directly stimulate the center of thermoregulation in hypothalamus, affect the procedure of human body heat production and loss, and cause delayed allergy.

A series of simple alkyl esteric and etheric derivatives of puerarin had been synthesized via the modification of phenolic hydroxyl group and alditolic hydroxyl groups and their effects on blood flow of rabbit ocular

tissue (Yang Ruolin, Li Na, et al., *Zhongguo Yaoke Daxue Xuebao (Journal of China Pharmaceutical University)*, 1999, 30(2):81-85; Hou Dianjie, Wang Jianwu, Sun Jianlong, *Zhongguo Yaowu Huaxue Xuebao (Chinese Journal of Medicinal Chemistry)*, 2002, 12(2):103-4). However, the pharmacodynamic actions and toxicities of these compounds on cardio- and cerebrvascular diseases, diabetes and alcoholism are not studied deeply.

In the prior arts, it is also disclosed that puerarin has poor water-solubility and lipo-solubility, and the solubility of puerarin in water is 0.462g/100ml. Solubilizers should be added during the preparations, and common solubilizers are propylene glycol, polyvinylpyrrolidone (PVP), etc. The solubility of puerarin in 4.3% PVP aqueous solution is 1.332g/100ml. The solubility of puerarin also depends on pH value, and puerarin in an aqueous solution has a poor stability at a relatively high pH value. The pH generally should be controlled at 6.5 or lower during the complexing and dissolving procedure (Wu Zhenghong, Zhu Yanqin, et al., *Jiangsu Yaoxue Yu Linchuang Yanjiu (Jiangsu Pharmaceutical and Clinical Researches)*, 1999, 7(1): 9-12).

The prior art further discloses that puerarin has a relatively low oral bioavailability of about 30%, and is administered by intravenous injection in clinic. The poor water-solubility, oral bioavailability and adverse effects of puerarin render the value of puerarin as pharmaceuticals.

So far, no document has been found that relates to the puerarin-based compounds of the present invention, i.e., C-Glycosylisoflavones having alkylaminoalkoxyl substituent, and to the use of these compounds for the treatment and prevention of cardio- and cerebrovascular disease, diabetes, and chemical poisoning.

SUMMARY OF THE INVENTION

One object of the present invention is to provide

C-Glycosylisoflavones having alkylaminoalkoxyl substituent in order to overcome the drawbacks in the prior arts.

Another object of the present invention is to provide a process for the preparation of the C-Glycosylisoflavones having alkylaminoalkoxyl substituents.

Yet another object of the present invention is to provide a pharmaceutical composition comprising one or more such compounds.


A further object of the present invention is to provide a use of said compounds in a medicament for treatment and prevention of diseases associated with cardio- and cerebrovascular diseases, in particular hypoxic-ischemic diseases.

One another object of the present invention is to provide a use of said compounds in a medicament for the treatment and prevention of diabetes and complications thereof.

Yet further object of the present invention is to provide a use of said compounds in a medicament for the treatment and prevention of chemical poisoning, in particular alcoholism.

For achieving the objects of the present invention, the present invention employs the following technical solutions:

The present invention relates to a novel alkylaminoalkoxyl-substituted C-Glycosylisoflavone or a pharmaceutically acceptable salt thereof:



wherein, R₁ and R₂ are independently selected from hydrogen,

dimethylaminoethyl, diethylaminoethyl, di(n-propyl)aminoethyl, di(iso-propyl)aminoethyl, di(n-butyl)aminoethyl, di(iso-butyl)aminoethyl, di(tert-butyl)aminoethyl, pyrrolidinylethyl, piperidylethyl, morpholinylethyl, piperazinylethyl, N-methylpiperazinylethyl, N-ethylpiperazinylethyl, tert-butylaminoethyl, dicyclohexylaminoethyl; dimethylaminopropyl, diethylaminopropyl, di(n-propyl)aminopropyl, di(iso-propyl)aminopropyl, di(n-butyl)aminopropyl, di(iso-butyl)aminopropyl, di(tert-butyl)aminopropyl, pyrrolidinylpropyl, piperidylpropyl, morpholinyl-propyl, piperazinylpropyl, N-methylpiperazinylpropyl, N-ethylpiperazinylpropyl, tert-butylaminopropyl, dicyclohexylaminopropyl; dimethylaminobutyl, diethylaminobutyl, di(n-propyl)aminobutyl, di(iso-propyl)aminobutyl, di(n-butyl)aminobutyl, di(iso-butyl)aminobutyl, di(tert-butyl)aminobutyl, pyrrolidinylbutyl, piperidylbutyl, morpholinylbutyl, piperazinylbutyl, N-methylpiperazinylbutyl, N-ethylpiperazinylbutyl, tert-butylaminobutyl, dicyclohexylaminobutyl; R₁ and R₂ do not simultaneously represent hydrogen; R₃ is selected from hydrogen, propionyl, butyryl, isobutyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethylpropionyl, valeryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, lauroyl. The pharmaceutically acceptable salts are selected from salts of various pharmaceutically acceptable organic acids and inorganic acids comprising hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid, methane sulfonic acid, p-toluene sulfonic acid, maleic acid, fumaric acid, tartaric acid, and various natural or non-natural amino acids.

The process of the present invention for preparing the compounds of formula (I) comprises: reacting puerarin as raw material with a suitable bifunctional compound at a room- to reflux- temperature in a suitable solvent under the presence of a base, which is firstly mono-etherified followed by amination. Specifically, the suitable bifunctional compound includes bihalogenated hydrocarbons, alkylene bissulfonates, and halogenated

hydrocarbon monosulfonates, such as 1,2-dichloroethane, 1,2-dibromoethane, 1,2-diiodoethane, 1,2-dichloropropane, 1,2-dibromopropane, 1,2-diiodopropane, 1,3-dichloropropane, 1,3-bromopropane, 1,3-diiodopropane, 1,2-dichlorobutane, 1,2-dibromobutane, 1,2-diiodobutane, 1,4-dichlorobutane, 1,4-dibromobutane, 1,4-diiodobutane, 1,2-ethylenedissulfonate, 1,2-propylene dissulfonate, 1,3-propylenedissulfonate, 1,2-butylenedissulfonate, 1,3-butylene dissulfonate, and 1,4-butylene dissulfonate, etc. The solvent includes water, acetone, dimethylformamide, dimethyl sulfoxide, and lower alcohols, wherein the lower alcohol is selected from methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, pentanol, 2,2-dimethyl-propan-1-ol, pentan-2-ol, pentan-3-ol and hexanol, etc.

The compounds of the present invention have better solubility in water at normal temperature than that of puerarin.

The present invention further relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of formula (I) and a pharmaceutically acceptable carrier.

The pharmacological studies indicated that the compounds of formula (I) have effects of vasodilatation, can significantly prolong the time to death caused by hypoxia in mice, and show protection effects on ex vivo cardiac postischemic reperfusion damage in rats. The compounds of the present invention have effects of vasodilatation, which have coronary artery and cerebral vessel dilation effect, reduction of myocardial consumption of oxygen, microcirculation improvement and antiplatelet effects, and have potential effects for the prevention of cardiocerebral hypoxia-ischemia.

The compounds of the present invention are novel compounds having the skeleton of puerarin, and can be used for the prevention and treatment of coronary artery diseases, various angina pectoris attacks, myocardial infarcts, cerebrovascular diseases, diabetes and complications thereof, and chemical poisoning, in particular alcoholism.

The pharmaceutical composition comprising an effective amount of the compound of the present invention can be prepared via utilizing common known pharmaceutically acceptable carriers in the art.

The compounds of the present invention or compositions thereof can be administered orally or parenterally. Oral formulations may be tablets, capsules and coated drugs, and parenteral formulations may be injections and suppositories, etc. These preparations can be prepared via utilizing common known methods familiar to those skilled in the art. To prepare tablets, capsules and coated drugs, the accessories may be conventional accessories, such as starch, gelatin, Arabia gum, silica, polyethylene glycol; solvents for liquid preparations may be, such as water, ethanol, propylene glycol; vegetable oils may be, such as corn oil, peanut oil, olive oil, etc. The preparations comprising the compounds of the present invention may further comprise other accessory ingredients, such as surfactants, lubricants, disintegrants, preservatives, correctants, coloring materials, etc. On the other hand, the water-solubility of the compounds of the present invention is better than that of puerarin, thus the compounds of the present invention can readily form a preparation for systemic delivery for the prevention and treatment of cardio- and cerebrovascular diseases, diabetes and complications thereof, and chemical poisoning, in particular alcoholism.

The dosage of the compounds of the formula (I) of the present invention in tablets, capsules, coated drugs, injections and suppositories is calculated based on the amount of said compounds present in a unit dosage form. The amount of the compounds of formula (I) of the present invention in a unit dosage form is 10 to 500 mg in general, preferably 20 to 200 mg.

The present invention will be explained in detail by the following examples, but these examples are not intent to limit the protection scope of the present invention.

The instruments used in the present invention are: XY-1

Electrothermal Melting Point Meter (thermometer not calibrated) for the melting points; JNM-ECA-400 NMR Spectrometer for the NMR; and Zabspec Mass Spectrometer for MS.

Example 1:

4'-(3-bromopropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone (PC₃)

A 0.16g (4mmol) of sodium hydroxide was dissolved in 120ml of anhydrous ethanol, and 0.8g (1.92mmol) of puerarin was added and dissolved completely by heating and refluxing. After slightly cooling, 0.20ml (2mmol) of 1,3-dibromopropane was added dropwisely. The reaction was continued for 5 hours under reflux. When the reaction was finished, the solvent was removed by distillation, and the resultant residue was separated by silica gel column chromatography (methylenechloride: methanol = 8:1) to give 0.53g of white solid, yield 51.5%. mp:196-197°C.

¹H NMR (⁶DMSO) δ(ppm): 8.39 (1H,s,C₂-H), 7.95 (1H,d,J=8.7,C₅-H), 7.52 (2H,d,J=6,C_{2'},_{5'}-H), 7.01 (2H,d,J=6,C_{3'},_{6'}-H), 6.99 (1H,d,J=10,C_{1'}-H), 4.00 (2H,t-OCH₂-), 3.69 (2H,q,-CH₂Br), 2.28 (2H,m,-CH₂-).

Example 2:

4'-(4-bromobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone (PC₄)

A 0.16g (4mmol) of sodium hydroxide was dissolved in 120ml of anhydrous ethanol, and 0.8g (1.92mmol) of puerarin was added and dissolved completely by heating and refluxing. After slightly cooling, 0.25ml (2mmol) of 1,4-dibromobutane was added dropwisely. And the reaction was continued for 5 hours under reflux. When the reaction was finished, the solvent was removed by distillation, and the resultant residue was separated by silica gel column chromatography (methylenechloride: methanol = 8:1) to give 0.53g of white solid, yield 47.2%. mp:198°C.

FAB-MS, m/z(%): 552.1(M⁺+1,22).

¹H-NMR(d⁶DMSO)δ(ppm): 8.36 (1H,s,C₂-H), 7.96 (1H,d,J=9,C₅-H), 7.52 (2H,d,J=9,C_{2',5'}-H), 7.01 (2H,d,J=9,C_{3',6'}-H), 6.99 (1H,d,J=9,C₆-H), 4.86 (1H,d,J=10,C_{1''}-H), 4.06 (3H,m,-OCH₂-,C_{3'''}-H), 3.62 (2H,t,J=7,-CH₂Br), 2.02 (2H,m,-CH₂-), 1.99 (2H,m,-CH₂-).

Example 3:

4'-(3-N-piperidylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.13ml (1mmol) of piperidine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol:triethylamine = 200:1) and then was dissolved by an eluent (methylenechloride: methanol = 6:1), and the silica gel was removed by filtration to give 80mg of white solid, yield 52.9%. mp: 203-205°C.

FAB-MS, m/z (%):542(M⁺,100).

¹H-NMR(d⁶DMSO)δ(ppm): 8.31 (1H,s,C₂-H), 7.91 (1H,d,J=9,C₅-H), 7.51 (2H,d,J=9,C_{2',6'}-H), 6.97 (3H,q,J=9,C_{3',5'}-H,C₆-H). 4.83 (1H,d,J=10,C_{1''}-H), 4.01 (3H,mC_{3'''}-H,-OCH₂-), 1.84 (2H,m,-CH₂-), 1.51 (4H, HexahydropyridineC_{3,5}-H), 1.47 (2H, HexahydropyridineC₄-H).

Example 4:

4'-(3-N-morpholinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.10ml (1mmol) of morpholine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol) and then was dissolved by an eluent (methylenechloride:methanol = 6:1), and the

silica gel was removed by filtration to give 80mg of the title compound in the form of a white solid, yield 52.7%. mp:189-190°C.

FAB-MS, m/z(%):544.1(M⁺,55).

¹H-NMR(d⁶DMSO)δ(ppm): 8.35 (1H,s,C₂-H), 7.95 (1Hd,J=9,C₅-H), 7.51 (2H,dJ=9,C_{2',6'}-H), 7.00 (3H,dd,J=9,C_{3',5'}-HC₆-H). 4.85 (1H,d,J=10,C_{1''}-H), 4.06 (3H,m,C_{3''}-H, -OCH₂-), 3.62 (4H,t,MorpholineC_{2,6}-H), 2.48 (5H,m, -CH₂N-,Morpholine C_{3,5}-H), 2.0 (2H,p,-CH₂-).

Example 5:

4'-(3-N-pyrrolidinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.13ml (1mmol) of pyrrolidine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 90mg of white solid, yield 61.1%. mp:193-195°C.

FAB-MS,m/z(%): 555 (M⁺+22,78), 528 (M⁺,100).

¹H-NMR(d⁶DMSO)δ(ppm): 8.26 (1H,s,C₂-H), 7.82 (1H,d,J=9,C₅-H), 7.50 (2H,d,J=9, C_{2',6'}-H), 6.96 (2H,d,J=9,C_{3',5'}-H,), 6.95 (1H,d,J=9,C₆-H). 4.77 (1H, d, J=10, C_{1''}-H), 4.00 (3H, m,C_{3''}-H,-OCH₂-), 2.50 (4H,m, Pyrrolidine C_{2,5}-H), 1.89 (2H,m,-CH₂) 1.68 (4H,m,PyrrolidineC_{3,4}-H).

Example 6:

4'-(3-N-diethylaminopropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.10ml (1mmol) of diethylamine was added under stirring, and then

the reaction was performed in an autoclave at 90°C by heating for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylenechloride: methanol = 6:1), and the silica gel was removed by filtration to give 50mg of white solid, yield 33.8%. mp:200-203°C.

FAB-MS, m/z (%):552($M^+ + 22$,100), 530(M^+ ,44).

1H -NMR(d⁶DMSO) δ (ppm): 8.24 (1H,s,C₂-H), 7.79 (1H,d,J=8.7,C₅-H), 7.50 (2H,d,J=8.7,C₂,₆-H), 6.96 (2H,d,J=8.7,C₃,₅-H), 6.76 (1H, d, J=8.7, C₆-H), 4.74 (1H,d,J=10C₁..-H), 4.04 (3H,m,C₃..-H,-OCH₂-), 2.50 (10H, m, -(CH₂)₃N), 1.83 (2H,m,-CH₂-), 0.96 (7H,q,-CH₃).

Example 7:

4'-[3-N-di(n-propyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.14ml (1mmol) of di(n-propyl)amine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 40mg of white solid, yield 25.7%. mp:202-205°C.

FAB-MS, m/z(%): 580 ($M^+ + 22$,100), 558 (M^+ ,84).

1H -NMR(d⁶DMSO) δ (ppm): 7.90 (1H,s,C₂-H), 7.51 (1H,d,J=9,C₅-H), 7.47 (2H, d, J=8C₂,₆-H), 6.91 (2H,d,J=8,C₃,₅-H,C₆-H), 6.25 (1H, d, J=9, C₆-H), 4.57 (1H,d,J=10,C₁..-H), 4.03 (3H,m,C₃..-H,-OCH₂-), 2.50 (4H, m, -N(CH₂)₂), 1.83 (2H,m,-CH₂-), 0.85 (6H,t,-CH₃).

Example 8:

4'-[3-N-di(n-butyl)aminopropoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.14ml (1mmol) of di(n-butyl)amine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 90mg of white solid, yield 55.1%. mp:198-199°C.

FAB-MS,m/z(%):586(M⁺,12).

¹HNMR (d⁶DMSO) δ(ppm): 8.04 (1H,s,C₂-H), 7.59 (1H,d,J=9,C₅-H), 7.48 (2H, d, J=8.7,C_{2'',6''}-H), 6.92 (2H,dJ=8.7,C_{3'',5''}-H), 6.41 (1H,d,J=9,C₆-H), 4.64 (1H,d,J=9.8C_{1''}-H), 4.03 (3H, m,C_{3''}-H,-OCH₂-), 2.49 (4H, m, -N(CH₂)₂-), 1.82 (2H,m,-CH₂-), 1.27 (11H,m,-N(CCH₂CH₂)₂-), 0.86 (8H, t, -CH₃).

Example 9:

4'-(3-N-4-methylpiperazinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.12ml (1mmol) of 1-methylpiperazine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give

100mg of white solid, yield 64.4%. mp:217-219°C.

FAB-MS, m/z(%): 579 ($M^+ + 22, 100$), 557.2 ($M^+, 58$).

1H -NMR (d^6 DMSO) δ (ppm): 8.05 (1H,s,C₂-H), 7.66 (1H,d,J=9,C₅-H), 7.48 (2H,d,J=8, C_{2',6'}-H), 6.94 (2H,d,J=8,C_{3',5'}-H), 6.50 (1H,d,J=9,C₆-H). 4.69 (1H, d, J=10, C_{1''}-H), 4.03 (3H, m, C_{3''}-H, -OCH₂-), 2.49 (7H, m, -CH₂N(CH₂)₂-), 2.14 (3H,s,-NCH₃-), 1.07 (2H,p,-CH₂-).

Example 10:

4'-(3-N-ethylpiperazinylpropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₃ was dissolved in 15ml of anhydrous ethanol, 0.12ml (1mmol) of 1-ethylpiperazine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 110mg of white solid, yield 69.1%. mp: 225-226°C.

FAB-MS,m/z(%): 593 ($M^+ + 22, 80$), 571 ($M^+, 22$).

1H -NMR (d^6 DMSO) δ (ppm): 7.97 (1H,s,C₂-H), 7.58 (1H,d,J=9,C₅-H), 7.48 (2H,d,J=9,C_{2',6'}-H), 6.92 (2H,d,J=9,C_{3',5'}-H), 6.36 (1H,d,J=9,C₆-H), 4.64 (1H,d,J=10,C_{1''}-H), 4.03 (3H,m,C_{3''}-H,-OCH₂-), 1.88 (2H,p,-CH₂-), 0.98 (3H,t,-NCH₃).

Example 11:

4'-(4-N-piperidylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.13ml (1mmol) of piperidine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent

and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylenechloride: methanol = 6:1), and the silica gel was removed by filtration to give 100mg of white solid, yield 66.2%. mp:204-205°C.

FAB-MS, m/z (%):556(M⁺,54).

¹H-NMR (d⁶DMSO) δ(ppm): 8.36 (1H,s,C₂-H), 7.95 (1H,d,J=8,C₅-H), 7.53 (2H,d,J=8,C_{2',6'}-H), 7.03 (3H,t,J=8,C_{3',5'}-H,C₆-H). 4.82 (1H,d,J=10, C_{1''}-H), 4.05 (3H,m,C_{3''}-H,-OCH₂-), 3.42 (2H,m,-CH₂N), 3.00 (4H, tt, Hexahydropyridine C_{2,6}-H), 1.78 (13H,m,pyridineC_{3,4,5}-H, -CH₂CH₂-).

Example 12:

4'-(4-N-morpholinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.10ml (1mmol) of morpholine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol) and then was dissolved by an eluent (methylenechloride:methanol = 6:1), and the silica gel was removed by filtration to give 80mg of white solid, yield 52.8%. mp:195-197°C.

FAB-MS, m/z(%): 558(M⁺,43).

¹H-NMR (d⁶DMSO) δ(ppm): 8.35 (1H,s,C₂-H), 7.96 (1H,d,J=9,C₅-H), 7.52 (2H,d,J=9, C_{2',6'}-H), 6.98 (3H,t,J=9,C_{3',5'}-H,C₆-H). 4.85 (1H, d, J=10, C_{1''}-H), 4.00 (4H,m,C_{3''}-H,-OCH₂-), 3.69 (3H,t,-O(CH₂)₂-), 2.81 (4H, m, -N(CH₂)₂-), 2.58 (3H,m,-CH₂N-), 1.76 (2H,m,-CH₂-), 1.68 (2H,m,-CH₂-).

Example 13:

4'-(4-N-pyrrolidinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.13ml (1mmol) of pyrrolidine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylenechloride: methanol = 6:1), and the silica gel was removed by filtration to give 110mg of white solid, yield 74.7%. mp:198-199°C.

FAB-MS,m/z(%): 564 (M⁺+22,42), 542 (M⁺,100).

¹H-NMR (d⁶DMSO) δ(ppm): 8.16 (1H,s,C₂-H), 7.77(1H,d,J=9,C₅-H), 7.50 (2H, d, J=9, C_{2',6'}-H), 6.95 (2H,d,J=9,C_{3',5'}-H), 6.70 (1H,d,J=9,C₆-H). 4.75 (1H,d,J=10,C_{1''}-H), 4.02 (3H,m,C_{3''}--OCH₂-), 2.49 (6H,m,-CH₂N(CH₂)₂-), 1.68 (9H,m,-CH₂CH₂-,PyrrolidineC_{3,4}-H).

Example 14:

4'-(4-N-diethylaminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.10ml (1mmol) of diethylamine was added under stirring, and then the reaction was performed in an autoclave at 90°C by heating for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol:triethylamine = 200:1) and then was dissolved by an eluent (methylenechloride:methanol = 6:1), and the silica gel was removed by filtration to give 60mg of white solid, yield 40.6%. mp:206-207°C.

FAB-MS, m/z (%): 544 (M⁺,18).

¹H-NMR (d⁶DMSO) δ(ppm): 8.08 (1H,s,C₂-H), 7.62 (1H,d,J=9,C₅-H), 7.48 (2H,d,J=9,C_{2',6'}-H), 6.91 (2H,d,J=9,C_{3',5'}-H), 6.47 (1H,d,J=9,C₆-H), 4.68 (1H,d,J=10,C_{1''}-H), 4.01 (3H,m,C_{3''}--H,-OCH₂-), 2.41 (4H, m,

-N(CH₂)₂-), 1.75 (2H,p,-CH₂-), 1.58 (2H,p,-CH₂-), 0.92(6H,t,-CH₃).

Example 15:

4'-(4-N-di(n-propyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.14ml (1mmol) of di(n-propyl)amine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride:methanol = 6:1), and the silica gel was removed by filtration to give 40mg of white solid, yield 25.7%. mp:199-203°C.

FAB-MS, m/z(%):572(M⁺,100).

¹H-NMR (d⁶DMSO) δ(ppm): 8.39 (1H,s,C₂-H), 7.95 (1H,d,J=9,C₅-H), 7.51 (2H,d,J=8.7,C_{2'},_{6'}-H), 6.99 (2H,d,J=8.7,C_{3'},_{5'}-H), 6.88 (1H, d, J=9, C₆-H). 4.82 (1H,d,J=10,C_{1''}-H), 4.02 (3H,m,C_{3''}-H,-OCH₂-), 1.41-1.73 (11H,-CH₂CH₂-, -N(CCH₂)₂-), 0.86(8H,t-CH₃).

Example 16:

4'-(4-N-di(n-butyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.14ml (1mmol) of di(n-butyl)amine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give

100mg of white solid, yield 61.3%. mp:198-200°C.

FAB-MS,m/z(%):622(M⁺+22,100), 600(M⁺,100).

¹H-NMR (d⁶DMSO) δ(ppm): 8.10 (1H, s, C₂-H), 7.67 (1H, d, J=9, C₅-H), 7.49 (2H, d, J=9,C_{2',6'}-H), 6.94 (2H, d, J=9, C_{3',5'}-H), 6.52 (1H, d, J=9, C₆-H), 4.89 (1H, d, J=10, C_{1''}-H), 4.00 (3H,m,C_{3''}-H,-OCH₂-), 1.28 (8H, m, N(CCH₂CH₂)₂-), 0.88 (6H,t,-CH₃).

Example 17:

4'-(4-N-methylpiperazinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.12ml (1mmol) of 1-methylpiperazine was added under stirring, and then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 110mg of white solid, yield 70.9%. mp:225-228°C.

FAB-MS, m/z (%): 593(M⁺+22,84), 571(M⁺,38).

¹H-NMR (d⁶DMSO) δ(ppm): 7.99 (1H,s,C₂-H), 7.60 (1H,d,J=9,C₅-H), 7.48 (2H, d, J=9,C_{2',6'}-H), 6.93 (2H,d,J=9,C_{3',5'}-H), 6.39 (1H,d,J=9,C₆-H), 4.86 (1H,d,J=10,C_{1''}-H), 4.10 (3H,m,C_{3''}-H,-OCH₂-), 2.49 (8H, 1-Methyl-piperazine C_{2,3,5,6}-H), 2.13 (3H,s,-NCH₃).

Example 18:

4'-(4-N-ethylpiperazinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)-isoflavone

A 150mg (0.27mmol) of PC₄ was dissolved in 15ml of anhydrous ethanol, 0.13ml (1mmol) of 1-ethylpiperazine was added under stirring, and

then was heated and refluxed for 9 hours. When the reaction was finished, the solvent and the excessive amine were removed by vacuum distillation. The obtained product was separated by silica gel chromatography (methanol: triethylamine = 200:1) and then was dissolved by an eluent (methylene-chloride: methanol = 6:1), and the silica gel was removed by filtration to give 110mg of white solid, yield 69.2%. mp:228-230°C.

FAB-MS, m/z (%): 607($M^+ + 22$, 96), 585(M^+ , 54).

1H -NMR (d^6 DMSO) δ (ppm): 8.02 (1H, s, C₂-H), 7.64 (1H, d, J=9, C₅-H), 7.48 (2H, d, J=9, C_{2',6'}-H), 6.93 (2H, d, J=9, C_{3',5'}-H), 6.45 (1H, d, J=9, C₆-H), 4.68 (1H, d, J=10, C_{1''}-H), 4.06 (3H, m, C_{3''}-H, -OCH₂-), 2.38 (11H, t, 1-Ethylpiperazine C_{2,3,5,6}-H), 1.74 (2H, t, -CH₂-), 1.58 (2H, m, -CH₂), 0.99 (3H, t, -CH₃).

Test example 1: in vitro experiment of vessel ring dilatation

This test was carried out according to a conventional method well known by the person skilled in the art.

Wistar rats were sacrificed by decapitation and subjected to thrcolaparotomy quickly. Aorta in thoracic and abdominal cavity was excised and placed in a culture dish containing vascular nutrition liquid. The peri-vascular tissues were removed and the aorta was cut to form strips of about 3mm-long, and each strip was penetrated carefully with two stainless wires of diameter about 0.1mm to form a triangular ring, then the ring was placed in a 37°C thermostatic bath containing 10mg of blood nutrition liquid, fixed and connected with a tension sensor and the signal thereof was further inputted into an automatic desktop balance recorder. A mixed gas of 95% O₂ and 5% was ventilated. After being stabilized, the drugs were screened. Noradrenaline was added to reach the maximum of vasoconstriction balance, and then 0.1ml of a solution of a drug-candidate was added to the bath, to a concentration of 10⁻⁵M, and was observed for 10 minutes. After changing the

liquids, noradrenaline was added to reach the maximal vasoconstriction, and the integrality of blood vessel endothelium was verified by 10^{-6} M of Ach. measuring the recordation diagram to obtain the maximum vasoconstriction Measuring of the maximal contraction rate and the contraction rate after administration, and the vasodilatation rates were calculated therefrom.

Test example 2: normal pressure hypoxia-resistance test in mice

This test was carried out by a common method familiar to those skilled in the art. 32 Kunming mice (16 males vs. 16 females, body weights ranging from 18 to 20g) were randomly divided into a control group and a administration group (each group having 16 animals), wherein the dosage was 60mg/Kg mouse and 0.2ml for each animal. After 0.5 hours of the intraperitoneal injection of test solutions, the mice were placed and sealed in 250ml wide-mouthed bottles with ground stoppers. The times of death were recorded. Statistical analysis was conducted separately with respect to the blank control group and puerarin group, and P values were calculated.

Table. Results of hypoxia-resistant activities

<i>Compounds of examples</i>	<i>Time to death (min)</i>	<i>P₁(blank)</i>	<i>P₂ (puerarin)</i>
Physiological saline	37.5±4		
Physiological saline + CMC	37.8±5		
Physiological saline + CMC + puerarin	48.3±5	<0.05	<0.05
Example 3	‡		
Example 4	75.3±7	<0.05	<0.05
Example 5	‡		
Example 6	73.5±9	<0.05	<0.05
Example 7	69.8±5	<0.05	<0.05
Example 8	43.2±9	<0.05	<0.05
Example 9	69.4±11	<0.05	<0.05
Example 10	54.7±8	>0.05	>0.05
Example 11	39.4±6	>0.05	>0.05
Example 12	40.7±10	>0.05	>0.05
Example 13	‡		
Example 14	79.1±8	<0.05	<0.05
Example 15	34.3±6	>0.05	>0.05
Example 16	36.9±7	>0.05	>0.05
Example 17	59.8±7	<0.05	>0.05
Example 18	75.9±6	<0.05	<0.05


‡ represents that the mice died during the standing after administered; and “P < 0.05” means that the time of death of the mice were significantly prolonged by the compound in comparison with the blank group and puerarin group.

According to the above test results, the person skilled in the art can well understand that the compounds of the present invention have effect of hypoxia-resistance effects on mammals.

The present invention is promising in the manufacture of medicaments for the treatment of cardio- and cerebrovascular diseases in mammalians including human, particularly medicaments for the treatment of hypoxia and ischemia. The present invention has potential value in the manufacture of medicaments for the treatment of diabetes and complications thereof, and medicaments for the treatment of chemical poisoning, particularly alcoholism.

WHAT IS CLAIMED IS:

1. A C-Glycosylisoflavone compound of the formula (I) having alkylaminoalkoxyl substituent or a pharmaceutically acceptable salt thereof:



wherein, R₁ and R₂ are independently selected from hydrogen, (C₁-C₁₂) linear or branched alkylamino or arylamino (C₁-C₆)alkyl; R₃ is selected from hydrogen, (C₁-C₁₂) linear or branched saturated acyl, or C₆₋₁₄ aryl carbonyl; wherein R₁ and R₂ do not represent hydrogen simultaneously; the 1-position of D-glucosyl is connected with the 8-position of the isoflavone in a form of β-configured C-glycoside.

2. The compound according to claim 1, characterized in that in formula (2), R₁ and R₂ are independently selected from hydrogen, dimethylaminoethyl, diethylaminoethyl, di(n-propyl)aminoethyl, di(iso-propyl)aminoethyl, di(n-butyl)aminoethyl, di(iso-butyl)aminoethyl, di(tert-butyl)aminoethyl, pyrrolidinylethyl, piperidylethyl, morpholinylethyl, piperazinylethyl, N-methylpiperazinylethyl, N-ethylpiperazinylethyl, tert-butylaminoethyl, dicyclohexylaminoethyl, dimethylaminopropyl, diethylaminopropyl, di(n-propyl)aminopropyl, di(iso-propyl)aminopropyl, di(n-butyl)aminopropyl, di(iso-butyl)aminopropyl, di(tert-butyl)aminopropyl, pyrrolidinylpropyl, piperidylpropyl, morpholinylpropyl, piperazinylpropyl, N-methylpiperazinylpropyl, N-ethylpiperazinylpropyl, tert-butylaminopropyl,

dicyclohexylaminopropyl, dimethylaminobutyl, diethylaminobutyl, di(n-propyl)aminobutyl, di(iso-propyl)aminobutyl, di(n-butyl)aminobutyl, di(iso-butyl)aminobutyl, di(tert-butyl)aminobutyl, pyrrolidinylbutyl, piperidylbutyl, morpholinylbutyl, piperazinylbutyl, N-methylpiperazinylbutyl, N-ethylpiperazinylbutyl, tert-butyldimethylaminobutyl, dicyclohexylaminobutyl, wherein R₁ and R₂ do not represent hydrogen simultaneously; R₃ is selected from hydrogen, propionyl, butyryl, isobutyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethylpropionyl, valeryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, lauroyl; or a pharmaceutically acceptable salt selected from the salts of hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid, methane sulfonic acid, p-toluene sulfonic acid, maleic acid, fumaric acid, tartaric acid, and various natural or non-natural amino acids.

3. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-N-piperidylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
4. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-N-morpholinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
5. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-N-pyrrolidinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
6. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-diethylaminopropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-di(n-propyl)aminopropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
8. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-di(n-butyl)aminopropoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
9. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-(4-methylpiperazinyl)propoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
10. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(3-(4-ethylpiperazinyl)propoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
11. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-N-piperidylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
12. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-N-morpholinylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
13. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-N-pyrrolidinylbutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-diethylaminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
15. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-di(n-propyl)aminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl) isoflavone or a pharmaceutically acceptable salt thereof.
16. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-(4-di(n-butyl)aminobutoxy)-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
17. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-[4-(4-methylpiperazinyl)butoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
18. The compound according to claim 1 or 2, wherein the compound of the formula (I) is 4'-[4-(4-ethylpiperazinyl)butoxy]-7-hydroxy-8- β -D-(1-deoxyglucosyl)isoflavone or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a compound of any one of claims 1 to 18 and a pharmaceutically acceptable carrier.
20. A preparation method of a compound of any one of claims 1 to 18, characterized in comprising, reacting puerarin material with a suitable bis-functional group substituted compound such as a bihalogenated hydrocarbon, an alkylene bissulfonate, or a halogenated hydrocarbon monosulfonate etc., in a suitable solvent selected from water, acetone, dimethylformamide, dimethyl sulfoxide, and lower alcohols, under the

presence of a base, an ambient to reflux- temperature, which is firstly mono-etherified followed by amination and/or salt-formation, to give the corresponding alkylaminoalkoxyl-substituted C-Glycosylisoflavone compound or a pharmaceutically acceptable salt thereof.

21. Use of a compound of any one of claims 1 to 18 in the manufacture of a medicament for the treatment of cardio- and cerebrovascular diseases as well as a medicament for the treatment of hypoxia or ischemia.
22. Use of a compound of any one of claims 1 to 18 in the manufacture of a medicament for the treatment of diabetes as well as diabetic complications.
23. Use of a compound of any one of claims 1 to 18 in the manufacture of a medicament for the treatment of chemical poisoning, particularly alcoholism.